Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 27;29(8):taac109.
doi: 10.1093/jtm/taac109.

Duration of immune protection of SARS-CoV-2 natural infection against reinfection

Hiam Chemaitelly  1   2   3 , Nico Nagelkerke  1 , Houssein H Ayoub  4 , Peter Coyle  5   6   7 , Patrick Tang  8 , Hadi M Yassine  6   9 , Hebah A Al-Khatib  6   9 , Maria K Smatti  6   9 , Mohammad R Hasan  8 , Zaina Al-Kanaani  5 , Einas Al-Kuwari  5 , Andrew Jeremijenko  5 , Anvar Hassan Kaleeckal  5 , Ali Nizar Latif  5 , Riyazuddin Mohammad Shaik  5 , Hanan F Abdul-Rahim  10 , Gheyath K Nasrallah  6   9 , Mohamed Ghaith Al-Kuwari  11 , Adeel A Butt  3   5   12 , Hamad Eid Al-Romaihi  13 , Mohamed H Al-Thani  13 , Abdullatif Al-Khal  5 , Roberto Bertollini  13 , Laith J Abu-Raddad  1   2   3   10
Affiliations

Duration of immune protection of SARS-CoV-2 natural infection against reinfection

Hiam Chemaitelly et al. J Travel Med. .

Abstract

Background: The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated the duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection and protection against severe reinfection, in Qatar, between 28 February 2020 and 5 June 2022.

Methods: Three national, matched, retrospective cohort studies were conducted to compare the incidence of SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) severity among unvaccinated persons with a documented SARS-CoV-2 primary infection, to incidence among those infection-naïve and unvaccinated. Associations were estimated using Cox proportional hazard regression models.

Results: Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% [95% confidence interval (CI): 84.8-86.2%]. Effectiveness peaked at 90.5% (95% CI: 88.4-92.3%) in the 7th month after the primary infection, but waned to ~ 70% by the 16th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22nd month and < 10% by the 32nd month. Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI: 36.3-39.8%) and declined with time since primary infection. A Gompertz curve suggested an effectiveness of < 10% by the 15th month. Effectiveness of primary infection against severe, critical or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9-98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age.

Conclusions: Protection of natural infection against reinfection wanes and may diminish within a few years. Viral immune evasion accelerates this waning. Protection against severe reinfection remains very strong, with no evidence for waning, irrespective of variant, for over 14 months after primary infection.

Keywords: COVID-19; Omicron; cohort study; epidemiology; immunity; reinfection; severe disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Cumulative incidence of infection in the pre-Omicron Reinfection Study. (B) Cumulative incidence of infection in the Omicron Reinfection Study. (C) Cumulative incidence of severe, critical or fatal COVID-19 in the COVID-19 Severity Reinfection Study.
Figure 2
Figure 2
(A) Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection. (B) Effectiveness of pre-Omicron primary infection against Omicron reinfection. (C) Effectiveness of primary infection with any variant against severe, critical or fatal COVID-19 due to reinfection with any variant.
Figure 3
Figure 3
Extrapolated effectiveness of pre-Omicron primary infection against pre-Omicron reinfection, and extrapolated effectiveness of pre-Omicron primary infection against Omicron reinfection.
See this image and copyright information in PMC

References

    1. Subissi L, von Gottberg A, Thukral L et al. An early warning system for emerging SARS-CoV-2 variants. Nat Med 2022; 28:1110–5. - PMC - PubMed
    1. Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to endemicity. Science 2021; 371:741–5. - PMC - PubMed
    1. Abu-Raddad LJ, Chemaitelly H, Bertollini R, National Study Group for COVID-19 Epidemiology . Severity of SARS-CoV-2 reinfections as compared with primary infections. N Engl J Med 2021; 385:2487–9. - PMC - PubMed
    1. Chemaitelly H, Tang P, Hasan MR et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med 2021; 385:e83. - PMC - PubMed
    1. Andrews N, Stowe J, Kirsebom F et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022; 386:1532–46. - PMC - PubMed

Supplementary concepts